Report from Annual General Meeting in SyntheticMR AB

The Annual General Meeting (AGM) of SyntheticMR AB (publ) was held on May 5, 2020, whereby the meeting resolved in accordance with the Nomination Committee and Board's proposed resolutions. The full resolutions are stated in the notice of the meeting.
 

The following resolutions were made at the AGM:

The AGM resolved to approve the Board's dividend proposal that the profits available to the Meeting should be allocated so that the shareholders will be paid SEK 1.50 per share. The remaining capitalized funds of SEK 30,766,834 including the share premium reserve and retained earnings, are carried forward.

The AGM resolved to grant the Board of directors and CEO discharge.

The AGM decided that the Board should consist of 4 ordinary members and no deputies. The AGM resolved on the election of Board member Petra Apell, and also re-election of the Board members, Jan Bertus Marten Warntjes, Johan Sedihn and Staffan Persson. Further, the AGM decided to elect Johan Sedihn as the Chairman of the Board.

The AGM resolved that a Nomination Committee should be appointed by the Annual General Meeting instructing the Chairman of the Board to contact the three largest shareholders (hereby both direct registered shareholders and nominee-registered shareholders) in accordance with Euroclear Sweden AB's printout of the share register as of September 30, 2020.

For further information, please contact Ulrik Harrysson, CEO SyntheticMR AB, +46 70 529 29 87 or Johanna Norén, Interim CFO SyntheticMR AB, +46 70 619 21 00.

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB’s product SyMRI® delivers multiple contrast images and quantitative data from a single 6-minute scan. The product is available in different packages. SyMRI IMAGE supports faster MRI workflows and improved patient throughput. SyMRI NEURO delivers automatic segmentation of brain tissue, supporting objective decision support. SyMRI is CE-marked and FDA 510(k) cleared. SyMRI is a registered trademark in Europe and in the USA. SyntheticMR is listed on the Spotlight Stock Market in Stockholm, Sweden. For additional information, please visit www.syntheticmr.com.